: Novo Nordisk boosts sales and profit outlook, buoyed by Ozempic and Wegovy

Brighter projections may suggest more supply of popular weight-loss drugs by year end, analysts say.

Previous post Key Words: Hedge fund billionaire Leon Cooperman doesn’t see S&P 500 above 4,600. Here’s what he’s investing in.
Next post Economic Report: U.S. consumer sentiment drops sharply in October to lowest level since May